SHANGHAI, January 27, 2026 — Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-powered online healthcare solutions, released an optimistic profit projection for 2025. It cited stronger-than-expected revenue growth and its first full year of profitability, highlighting the commercial feasibility of its “AI + chronic care services” model.
In a filing issued on January 25, the firm stated it anticipates 2025 full-year revenue to range between RMB 3.5 billion and RMB 3.55 billion, representing an approximate 30% year-on-year increase. Fangzhou also projected a net profit of RMB 7 million to RMB 10 million, marking a shift to full profitability following its achievement of adjusted profitability in 2024.
The company attributed the revenue rise primarily to the ongoing expansion of its chronic disease management services rooted in trusted doctor-patient relationships, as well as the enhancement of its platform via AI technologies. These factors have attracted a growing number of physicians and patients, fueling sustained growth in its consumer-facing business. The transition to profitability was further supported by a larger revenue scale and a reduction in equity-settled and share-based payments.
Fangzhou noted that the earnings improvement reflects a qualitative shift in its core business fundamentals, validating the long-term sustainability of its chronic disease management model. The Company operates one of China’s largest “AI + chronic disease management” platforms, benefiting from rising healthcare demand amid an aging population and increasing preference for accessible, tech-enabled medical services.
In 2025, the Company completed a key strategic upgrade to its “AI + H2H (Hospital-to-Home)” model, integrating AI across the entire service chain. In September 2025, Fangzhou began benchmarking against OpenEvidence and accelerated its large-model deployment, finalizing key technical positioning nearly six months ahead of many peers—further strengthening its leadership in AI-driven healthcare.
External research institutions have also taken notice. Citi Research initiated coverage of Fangzhou in mid-2025 with a “Buy” rating and a target price of HK$8.50. Separately, the Gelonghui Research Institute stated in an early 2026 report that the Company’s revenue is expected to reach HK$3.5 billion in 2025 and HK$4.8 billion in 2026, adding that Fangzhou is entering a period of value re-rating driven by scale expansion and improving profitability.
Looking ahead, Fangzhou will continue to refine its AI + H2H full-cycle smart healthcare ecosystem, deepen technological research and service innovation, and leverage its platform capabilities to support China’s “Healthy China 2030” initiative while setting benchmarks for high-quality development in the digital healthcare industry.
About Tencent Healthcare
Tencent Healthcare, Tencent’s healthcare service platform, leverages the WeChat ecosystem and artificial intelligence technologies to build an integrated service system.
About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering personalized medical care and AI-enabled precision medicine solutions. For more information, visit .
Media Contact
For further inquiries or interview requests, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements
